We aimed to evaluate and compare hypothalamic–pituitary–adrenal (HPA) axis suppression, safety and efficacy of two novel formulations of clobetasol propionate 0.025% cream (formulation 5 [Impoyz®] and formulation 13) with the currently marketed clobetasol propionate 0.05% emollient cream (reference formulation) in Indian patients with moderate-to-severe psoriasis.

Two clobetasol formulations, formulation 5 and formulation 13, has similar efficacy and an improved systemic safety profile compared to the clobetasol propionate 0.05% (Temovate E®) cream in terms of HPA axis suppression.

Our study findings support the use of novel clobetasol propionate 0.025% cream formulations (formulation 5 and formulation 13) as an effective and safer treatment option for patients with moderate-to-severe psoriasis.